Why is Alkem Laboratories Ltd falling/rising?

Consistent Outperformance Against Benchmarks

Alkem Laboratories has demonstrated impressive returns relative to the broader market indices. Over the past week, the stock surged by 5.61%, significantly outperforming the Sensex, which declined by 1.83% during the same period. This trend extends over longer durations as well, with the stock delivering a 10.01% return over the last year compared to the Sensex’s 8.40%. Even more striking is the three-year performance, where Alkem Laboratories has nearly doubled investors’ capital with a 92.26% gain, far surpassing the Sensex’s 39.89% rise. Such consistent outperformance underscores the company’s resilience and appeal amid varying market conditions.

Technical Strength and Rising Investor Interest

On the technical front, the stock has been on a steady ascent, hitting a new 52-week high of ₹5,880.95 on 12-Jan. It has maintained a positive trajectory for five consecutive days, accumulating a 5.61% gain in that span. The share price currently trades above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling strong bullish momentum. This technical strength is further supported by a surge in investor participation; delivery volumes on 9-Jan rose sharply by 138.14% compared to the five-day average, indicating heightened confidence among shareholders and increased liquidity that facilitates sizeable trades.

Fundamental Strength and Valuation Metrics

Alkem Laboratories’ rise is also underpinned by solid fundamentals. The company boasts a high return on equity (ROE) of 16.90%, reflecting efficient management and effective utilisation of shareholder capital. Its debt-to-equity ratio remains at zero, indicating a conservative capital structure with minimal financial risk. The stock’s price-to-book value stands at 5.3, which is considered fair relative to its peers and historical valuations. Over the past year, profits have grown by 7.8%, complementing the 10.01% return generated for investors. However, the price-to-earnings-to-growth (PEG) ratio of 3.8 suggests that while the stock is fairly valued, growth expectations are already priced in, warranting a cautious but optimistic outlook.

Long-Term Market-Beating Performance

Beyond short-term gains, Alkem Laboratories has consistently outperformed the BSE500 index across multiple time horizons, including the last three years, one year, and three months. This sustained outperformance highlights the company’s ability to deliver value through both growth and stability, making it an attractive proposition for investors seeking exposure to the pharmaceuticals sector with a track record of resilience and steady returns.

Conclusion: Why Alkem Laboratories Is Rising

The rise in Alkem Laboratories’ share price on 12-Jan is a reflection of its strong market momentum, robust fundamentals, and favourable valuation metrics. The stock’s ability to outperform key benchmarks consistently, combined with rising investor participation and technical strength, has driven its recent gains. While the company maintains a conservative debt profile and delivers solid returns on equity, investors should note the relatively high PEG ratio, which suggests that much of the growth potential is already factored into the price. Nonetheless, the stock’s liquidity and steady profit growth make it a compelling option for those seeking exposure to a well-managed pharmaceutical firm with a proven track record of market-beating performance.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →